Concurrently, immunostaining for the proliferation marker Ki-67 was employed to further substantiate the suppressive effects of lenvatinib and avapritinib on tumor cell proliferation (Fig. 5H and Supplementary Figure S10). Here, MKI67 is linked to neoplasm.